Unknown

Dataset Information

0

Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.


ABSTRACT:

Background

Leiomyosarcoma (LMS) is the most common soft tissue and uterine sarcoma, but no standard therapy is available for recurrent or metastatic LMS. TP53, p16/RB1, and PI3K/mTOR pathway dysregulations are recurrent events, and some LMS express estrogen receptor (ER) and/or progesterone receptor (PR). To characterize relationships between these pathway perturbations, the authors evaluated protein expression in soft tissue and uterine nonprimary leiomyosarcoma (np-LMS), including local recurrences and distant metastases.

Methods

TP53, RB1, p16, and PTEN expression aberrations were determined by immunohistochemistry (IHC) in tissue microarrays (TMAs) from 227 np-LMS and a comparison group of 262 primary leiomyosarcomas (p-LMS). Thirty-five of the np-LMS had a matched p-LMS specimen in the TMAs. Correlative studies included differentiation scoring, ER and PR IHC, and CDKN2A/p16 fluorescence in situ hybridization.

Results

Dysregulation of TP53, p16/RB1, and PTEN was demonstrated in 90%, 95%, and 41% of np-LMS, respectively. PTEN inactivation was more common in soft tissue np-LMS than uterine np-LMS (55% vs 31%; P = .0005). Moderate-strong ER expression was more common in uterine np-LMS than soft tissue np-LMS (50% vs 7%; P < .0001). Co-inactivation of TP53 and RB1 was found in 81% of np-LMS and was common in both soft tissue and uterine np-LMS (90% and 74%, respectively). RB1, p16, and PTEN aberrations were nearly always conserved in p-LMS and np-LMS from the same patients.

Conclusions

These studies show that nearly all np-LMS have TP53 and/or RB1 aberrations. Therefore, therapies targeting cell cycle and DNA damage checkpoint vulnerabilities should be prioritized for evaluations in LMS.

SUBMITTER: Schaefer IM 

PROVIDER: S-EPMC8277678 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Leiomyosarcoma (LMS) is the most common soft tissue and uterine sarcoma, but no standard therapy is available for recurrent or metastatic LMS. TP53, p16/RB1, and PI3K/mTOR pathway dysregulations are recurrent events, and some LMS express estrogen receptor (ER) and/or progesterone receptor (PR). To characterize relationships between these pathway perturbations, the authors evaluated protein expression in soft tissue and uterine nonprimary leiomyosarcoma (np-LMS), including loca  ...[more]

Similar Datasets

2009-06-04 | GSE16384 | GEO
2010-05-18 | E-GEOD-16384 | biostudies-arrayexpress
2007-05-30 | GSE6472 | GEO
| S-EPMC4348062 | biostudies-literature
| S-EPMC6159989 | biostudies-literature
| S-EPMC7303928 | biostudies-literature
| S-EPMC5702876 | biostudies-literature
| S-EPMC2579482 | biostudies-literature
| S-EPMC3918305 | biostudies-literature
| S-EPMC10990278 | biostudies-literature